Management of pregnant patients with pulmonary arterial hypertension

Xiao Zhang¹,²,³ and Zhao Huangfu*¹

¹Department of Gynecology and Obstetrics, Beijing Hospital, National Center of Gerontology, Beijing, China, ²Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, ³Peking Union Medical College, Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. *Department of Urology, Shanghai Hospital, Naval Medical University, Shanghai, China

Pregnant individuals with pulmonary arterial hypertension (PAH) have significantly high risks of maternal and perinatal mortality. Profound changes in plasma volume, cardiac output and systemic vascular resistance can all increase the strain being placed on the right ventricle, leading to heart failure and cardiovascular collapse. Given the complex network of opposing physiological changes, strict contraception and reduction of hemodynamic fluctuations during pregnancy are important methods of minimizing the risk of maternal mortality and improving the outcomes following pregnancy. In this review, we discuss the recent research progress into pre-conception management and the various therapeutic strategies for pregnant individuals with PAH.

KEYWORDS: pregnancy, pulmonary arterial hypertension, management, therapy, preconception management

Introduction

Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary artery pressure and vascular resistance, leading to increased right ventricular afterload, dysfunction or even failure which can be fatal (1). In 2016, it was estimated that a PAH prevalence of ∼1% of the global population (2). Additionally, PAH prevalence in the United Kingdom has doubled in the last decade and is currently 125 cases/million person¹. PAH among pregnant women confers high risks of mortality for both the mother and fetus. The adverse outcomes of PAH are exacerbated by the physiologic changes of pregnancy, which contribute to a high maternal mortality reaching 30–56% and a high neonatal mortality reaching 13% (3). With the improved treatment of PAH, maternal mortality has declined but remains high, ranging 11–25% (4–8). Given the high risk following pregnancy, appropriate contraception and reduction of hemodynamic fluctuations during pregnancy is key to reducing this risk of maternal mortality and improving pregnancy outcomes. In this review, we summarized the

¹ NHS Digital. National Audit of Pulmonary Hypertension 10th Annual Report, Great Britain, 2018-19. Available online at: https://digital.nhs.uk/data-and-information/publications/statistical/national-pulmonary-hypertension-audit/2019 (accessed October 19, 2022).
classification systems of PAH, strategies devised for preconception counseling and treatment strategies developed that are or will soon become available for pregnant women with PAH.

Definition and classification

PAH is a heterogeneous disease that is characterized by an elevated mean pulmonary artery pressure of ≥20 mmHg at rest as per the 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines (1, 9). When echocardiographic tricuspid regurgitation velocity exceeds the threshold (>2.8 m/s), PAH should also be highly suspected according to the updated hemodynamic definition (10). It can be classified into the following five main groups based on the 2022 ESC/ERS guidelines: (i) Group 1, PAH; (ii) Group 2, PAH associated with left heart disease; (iii) Group 3, PAH associated with lung disease and/or hypoxia; (iv) Group 4, PAH associated with pulmonary artery obstructions; and (v) Group 5, PAH with unclear and/or multifactorial mechanisms (11) (Table 1).

Preconception management

Contraceptives

The 2022 ESC/ERS guidelines recommended that all patients with PAH should be treated with contraception using a strict regimen (9). Although pregnancy may be feasible in some PAH patients with well-controlled disease, a low-risk profile, and normal or near-normal resting hemodynamics, for women with poorly controlled disease or women without fertility requirements, effective contraception is essential in view of the possible harm caused by contraceptive failure (12). The use of progesterone-only oral contraceptives, condoms, intrauterine contraceptive devices, or emergency post-coital contraception after intercourse is effective for PAH patients (9, 13). However, considering the obstacles of drug-drug interactions, potential contraindications to hormonal interventions (e.g., thromboembolism) and unreliability of contraceptive tools, a number of reports previously proposed that a combination of two or more contraceptive methods should be used, especially for patients with PAH treated with endothelin receptor antagonists (14–16). Tubal ligation is also an effective way to achieve permanent contraception, but patients have to face some risks of anesthesia accidents and complications since it is an invasive procedure. Therefore, tubal ligation can be performed at the same time when a woman is undergoing another surgery, such as cesarean section, reducing the risk of multiple surgeries. In addition, micro-insertion hysteroscopic sterilization is one of the effective contraceptive methods for patients with PAH due to its apparently lower surgical risk (17, 18).

Preconception counseling

Because of high risk of adverse pregnancy outcomes and inherited heart defects (19, 20), the 2022 ESC/ERS guidelines recommended that women with PAH who are considering pregnancy or having already been pregnant should receive genetic counseling and shared decision-making at experienced medical centers (9). Fetal genetic testing should also be performed in pregnant women with known PAH-associated
TABLE 2 United States of America food and drug administration (FDA) pharmaceutical categories in pregnancy.

| Categories | Pregnancy risk |
|------------|----------------|
| A          | Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy, and there is no evidence of risk in later trimester. |
| B          | Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnancy women. |
| C          | Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. |
| D          | There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. |
| X          | Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risk involved in use of the drug in pregnant women clearly outweigh potential benefits. |

General management

Pregnant women with PAH should avoid excessive activity but should still be encouraged to be active within symptom limits (16, 80). Whenever possible, lateral position should always be taken to minimize the compression of the inferior vena cava in the third trimester. Elastic support stockings can also be used whilst walking to avoid drastic changes in blood volume. In addition, appropriate supplementation of iron and folic acid should be encouraged to prevent anemia, whereas vaccination at least against influenza, Streptococcus pneumoniae and SARS-CoV-2 before pregnancy is recommended to enhance immunity (9, 81, 82).

For patients with PAH who decide to continue pregnancy, a standardized, individualized and realistic diagnosis and treatment plan should be formulated. They should receive regular and stringent evaluation and examination by clinicians from multiple disciplinary backgrounds during the pregnancy period (83). Prenatal check-ups should be performed every 2 weeks before 20 weeks and then once a week after 20 weeks of gestation. In addition to the routine obstetric examination, classification of the primary disease causing PAH, primary symptoms of PAH, cardiac function, echocardiography, 6-min walk test and biochemical indicators, including platelet count, hemoglobin, brain natriuretic peptide levels and arterial blood gas analysis, should also be focused upon (23). Since fetuses of pregnant women with PAH typically exhibit different degrees of growth restriction, ultrasound should be performed to examine the status of fetal growth at each obstetric examination (7, 13, 23). Hospitalization would be required if the condition worsens. Management by a multidisciplinary team is necessary for pregnant women with moderate to severe PAH (mWHO II–IV). This expert team should at least include a cardiologist, an ophthalmologist and an anesthesiologist with expertise in managing high-risk pregnant women with cardiac diseases. Furthermore, according to the unique scenarios posed by each patient, to produce a detailed delivery and emergency plan that includes the possibility of extracorporeal membrane oxygenation (ECMO) or transplantation, other specialists, including those who with extensive knowledge in pharmacy, cardiothoracic surgery, fetal medicine, neonatology, hematology, nursing and respiratory medicine, should be involved (1, 84). In fact, considering the high prevalence of symptoms of depression, anxiety and adjustment disorders in patients with PAH, empathic and hopeful communication is also crucial for physicians caring for pregnant women with PAH (9).

Supportive therapy

Oxygen therapy

Oxygen inhalation is recommended when the peripheral oxygen saturation is <90% or arterial oxygen partial pressure...
| Classification | Drugs | FDA category permeable | Placenta permeable | Transfer to breast milk (fetal dose) | Pre-clinical/clinical safety data | Method | Dose | Common adverse reactions | Reference |
|----------------|-------|------------------------|-------------------|------------------------------------|----------------------------------|--------|------|--------------------------|----------|
| Anticoagulant  | Aspirin| C                      | Yes               | Yes (9–21%), potential toxicity, low dose (150 mg/d) may be indicated | Increase in gastrochisis in the first trimester and premature closure of the ductus arteriosus; cryptorchism; persistent pulmonary artery hypertension of the newborn in the third trimester; safe | Oral    | 100 mg qd | Gastric ulcer, hemorrhage | (25–33) |
|                | Fondaparinux | –                  | Yes (maximum of 10%) | Yes (rat) | Inadequate human data; use only when benefit outweigh risk | Rats/rabbits: subcutaneous doses up to 10 mg/kg/day in rats and at subcutaneous doses up to 10 mg/kg/day in rabbits revealed no evidence of impaired fertility or harm to the fetus | Inhalation | 5–10 mg/d | Hemorrhage | (34–37) |
| Heparin        | B     | No                     | No                | No                                  | Long-term use: less osteoporosis and thrombocytopenia than UFH, increased risk of maternal bleeding | Intravenous/inhalation | | | | (33, 38, 39) |

(Continued)
| Classification | Drugs | FDA category | Placenta permeable | Transfer to breast milk (fetal dose) | Pre-clinical/clinical safety data | Method | Dose | Common adverse reactions | Reference |
|----------------|-------|--------------|--------------------|----------------------------------|----------------------------------|--------|------|-------------------------|-----------|
|                |       |              |                    |                                  |                                  |        |      |                         |           |
|                | low molecular weight heparin (LMWH) | B | No | No | No increased risk of major developmental abnormalities | Inhalation | 1 dose/d | Hemorrhage | (33, 40–44) |
|                | Warfarin | D | Yes | Yes (maximum of 10%) | Coumarin embryopathy, bleeding | Oral | Adjust according to INR | Hemorrhage, gastrointestinal reaction, vasculitis | (33, 44–49) |
|                | Prostacyclin analog | B | Unknown | Unknown | Inadequate human data | Intravenous | Starting dose 2 ng/kg/min; Target dose determined by tolerability and effectiveness; typical dose range at 1 year is 16–30 ng/kg/min, with wide individual variability | Headache, flushing, gastrointestinal reaction | (9, 24, 50–54) |
|                | Epoprostenol | B | Unknown | Unknown | Rats and rabbits: No impaired fertility or fetal harm | Intravenous | | | |

(Continued)
| Classification | Drugs | FDA category permeable | Placenta permeable | Transfer to breast milk (fetal dose) | Pre-clinical/clinical safety data | Method | Dose | Common adverse reactions | Reference |
|----------------|-------|------------------------|--------------------|-------------------------------|---------------------------------|--------|------|--------------------------|----------|
|                | Iloprost | C          | Unknown         | Unknown                   | Inadequate human data: use only when benefit outweigh risk | Inhalation | Starting dose 2.5 ug 6–9 times per day, Target dose 5.0 ug 6–9 times per day | Flushing, jaw pain, hypotension, cough, headache, flu-like syndrome, nausea, vomiting, syncope | (9, 24, 55–57) |

Rats: shortened digits of the thoracic extremity in fetuses and pu-ps (these alterations are considered to be haemodynamic alterations in the fetoplacental unit and not teratogenic). Sprague-Dawley rats and monkeys: no such digital anomalies or other gross structural abnormalities. In Sprague-Dawley rats, iloprost clathrate (13% iloprost) significantly increased the number of non-viable fetuses at a maternally toxic oral dosage of 250 mg/kg/day, and in Han-Wistar rats it was found to be embryolethal in 15 of 44 litters at an i.v. dosage of 1 mg/kg/day.
| Classification | Drugs | FDA category permeable | Placenta permeable | Transfer to breast milk (fetal dose) | Pre-clinical/clinical safety data | Method | Dose | Common adverse reactions | Reference |
|----------------|-------|------------------------|--------------------|-------------------------------------|----------------------------------|--------|------|--------------------------|-----------|
|                |       |                        |                    |                                     |                                  |        |      |                          |           |
| Human data     | Animal data |                      |                    |                                     |                                  |        |      |                          |           |
| Treprostinil   | B     | Unknown                | Unknown            | Inadequate human data: use only if needed | Rabbits: increased incidence of fetal skeletal variations | Oral/ intravenous/ inhalation | (Starting dose 0.25 mg bid/0.125 mg tid; Target dose maximum tolerated dose up to 1,600 ug bid)/(Starting dose 1.25 mg/kg/min; (Target dose determined by tolerability and effectiveness; typical dose range at 1 year is 25–60 mg/kg/min, with wide individual variability)/(Starting dose 18 ug 4 times per day; Target dose 54–72 ug 4 times per day) | Pain at the infusion site, headache, flushing, gastrointestinal reaction, cough, flu-like syndrome, nausea, vomiting, tongue pain, syncope | (9, 24, 58–65) |
| Calcium channel blocker | Diltiazem | C | No | Yes | Possible teratogenic effects. Use only when benefit outweigh risk | Mice, rats, and rabbits: embryo and fetal lethality, and abnormalities of the skeleton, heart, retina, and tongue, reductions in early individual pup weights and pup survival, prolonged delivery, and increased incidence of stillbirths | Oral | Edema, systemic hypotension, headache, nausea, dizzy, rash, fatigue | (9, 66–69) |

(Continued)
| Classification | Drugs          | FDA category | Placenta permeable | Transfer to breast milk (fetal dose) | Pre-clinical/clinical safety data                                                                 | Method | Dose       | Common adverse reactions                                                                 | Reference |
|----------------|----------------|--------------|--------------------|-------------------------------------|--------------------------------------------------------------------------------------------------|--------|------------|------------------------------------------------------------------------------------------|-----------|
|                | Nifedipine     | C            | Yes                | Yes (maximum of 1.8%)               | Tocolytic; sublingual application and potential synergism with magnesium sulfate may induce hypotension (mother) and fetal hypoxia. No teratogenic effects in the first trimester. Increased perinatal asphyxia, cesarean delivery, prematurity, and intrauterine growth retardation | Oral    | Starting dose 10 mg bid; Target dose 20–60 mg bid/tid | Edema, systemic hypotension, dizzy, headache, nausea, fatigue, flushing | (9, 66, 69, 70) |
|                | Phosphodiesterase inhibitor | B          | Unknown            | Unknown                             | Inadequate human data                                                                                 | Oral    | 20 mg tid | Headache, flushing, epistaxis, dyspepsia, rhinobyon, paropsia, backache, dizzy, rash     | (24, 71–77) |
|                | Sildenafil      | B            | Unknown            | Unknown                             | Rats/rabbits: No teratogenicity, embryotoxicity, or fetotoxicity during organogenesis                  | Oral    | –          | Abdominal pain, constipation, flatulence, fatigue, headache                              | (66, 78, 79) |
|                | Lipid-lowering drugs | X          | Yes                | Unknown                             | Congenital anomalies, but recent studies have found no significant increase in birth defects          | Oral    | –          | –                                                                                            | –         |
is <60 mmHg. Maintaining the arterial partial pressure of oxygen at >70 mmHg and the oxygen saturation at >92% can reduce pulmonary vascular resistance, right-to-left shunt and the incidence of low-birth-weight infants (85). Nocturnal oxygen therapy should be considered in case of sleep-related desaturation (86). Oxygen inhalation should also be considered when pregnant patients with PAH travel by air, especially those with New York Heart Association (NYHA) class III-IV PAH or with the arterial partial pressure of oxygen <8 kPa (87, 88). Although oxygen administration reduces pulmonary vascular resistance and improves exercise tolerance in patients with PAH, there are no data to suggest that long-term oxygen therapy has sustained benefits on the course of the disease (9).

Diuretics, cardiotonics and antiarrhythmics

Diuretics can relieve the symptoms of decompensation following right heart failure. Torasemide or furosemide are options of loop diuretics during pregnancy. However, spironolactone should be avoided during the first trimester because due to its antiandrogenic effects (13, 66, 89, 90). During the use of diuretics, regular monitoring of kidney function and serum electrolytes is necessary to avoid intravascular volume depletion and further decline in cardiac output and systemic blood pressure.

Cardiac agents, including digoxin or milrinone, can improve cardiac output in patients with PAH, although their long-term efficacy remains unclear. In addition, maintenance of sinus rhythm is important, because atrial fibrillation and supraventricular tachycardia are associated with the occurrence of right heart failure and subsequent mortality (91). Intravenous adenosine is the priority treatment method for acute episodes of paroxysmal supraventricular tachycardia (PSVT). By contrast, β-adrenergic receptor blockers, with the exception of atenolol, are first-line drugs for PSVT prevention. Electrical cardioversion is also recommended when patients with atrial fibrillation become hemodynamically unstable or if they are considered to be at great risk of mortality (92). Ibutilide or flecainide injections may be considered to eliminate atrial fluttering and atrial fibrillation in PAH patients with structurally normal hearts (93). By the same token, since patients with congenital heart disease do not typically tolerate atrial flutter effectively, electrical cardioversion should be performed to restore sinus rhythm (94). Idiopathic right ventricular outflow tract tachycardia is the most common type of ventricular tachycardia, which requires β-adrenergic receptor blockers, verapamil or other antiarrhythmic prophylactics. If drug treatment fails, catheter ablation would then be needed. If possible, catheter ablation should be delayed until the second trimester and performed at a well-equipped medical center containing experts with extensive experience (95, 96). In addition, occasional sinus bradycardia may be associated with the supine hypotensive syndrome. Symptomatic bradycardia should be treated with changes in maternal position, following which temporary pacemaker should be installed if clinical symptoms persist (97, 98). Temporary pacemakers are usually not required in hemodynamically stable patients but are recommended during labor in women at risk of bradycardia or those with a history of syncope (97). Implantable cardioverter defibrillators should also be considered before pregnancy in patients at high risk of sudden cardiac death (80, 99).

Anticoagulant therapy

Pregnant women frequently present with hypercoagulability, which can increase the risk of thrombosis. Anticoagulants are recommended for reducing the risk of thrombosis if cardiopulmonary dysfunction was detected in the pregnant individual with PAH. The choice of anticoagulant drugs should be comprehensively considered based on the individual involved, gestational stage, risk of maternal bleeding and teratogenic effects (15, 100). Due to low molecular weight heparin (LMWH) having lower reported levels of impact on the fetus and lower risks in terms of osteoporosis, it is considered to be the priority drug for preventing and treating venous thromboembolism during pregnancy and puerperium. However, the preventive effect of valve thrombosis conferred by LMWH is weak (38). If LMWH or unfractionated heparin (UFH) is used during pregnancy, then it is recommended to calculate the initial dose according to the maternal weight in the first trimester (8–10 gestational weeks). The dose should be subsequently adjusted by monitoring the anti-factor Xa levels or partial thromboplastin time weekly until the 4- to 6-h peak anti-Xa levels reached 0.6–1.2 IU/ml (1, 101). Fondaparinux may even be considered for PAH patients if they are allergic to LMWH. Warfarin can pass through the placenta and may exert dose-dependent teratogenic effects, which can lead to “Fetal Warfarin Syndrome” (102). Therefore, warfarin should be used at limited dosages or be replaced with LMWH during the first trimester. The dosage of warfarin needs to be limited to <5 mg/d and the international normalized ratio (INR) should be adjusted to 1.5–2.0 during the second and third trimesters. However, the safety profile of warfarin in pregnant women remains controversial and should therefore be avoided where possible during pregnancy (40, 45, 103–106). In addition, high-quality evidence supporting the safety and efficacy of novel oral anticoagulants, such as dabigatran, rivaroxaban and apixaban, in pregnant women with remain elusive obstructing their recommendation for use (107, 108). A meta-analysis of 339 pregnant women on new direct oral anticoagulants previously revealed that 22.2% suffered from miscarriages, whilst 3.6% had fetuses with skeletal and facial deformities (109).

In particular, all patients had to terminate oral anticoagulation during the first 2 months of pregnancy, suggesting that the novel oral anticoagulation regimens used during pregnancy may be associated with higher risks of miscarriage and birth defects (110).
Oral anticoagulants should be replaced with LMWH or UFH 3–5 days before delivery, which would render it safer for cesarean sections. However, LMWH should be stopped 12–24 h before delivery, whereas UFH should be stopped >4–7 days before delivery. Protamine antagonism can be carefully applied for pregnant women requiring the emergency termination of pregnancy but did not stop heparin treatment. By contrast, warfarin can be antagonized by vitamin K1 antagonism (15, 111–113). If there is no obvious bleeding for 24 h after delivery, anticoagulation therapy can be resumed. It should however be noted that patients who were treated with warfarin prior should instead be administered with LMWH and have the INR monitored for several days after delivery. LMWH can then be stopped after warfarin comes into effect.

PAH-specific therapy

Currently available drugs targeting the pathological pathways underlying PAH did not result in the complete reversal of the condition but have been found to reduce pulmonary artery pressure and alleviate clinical symptoms. For patients with stable hemodynamics, routine use of vasodilators and other drugs that can interfere with hemodynamics is not recommended. However, for patients with unstable hemodynamics, addition of pulmonary vasodilators on cumulatively on the existing general treatment regimens can significantly reduce the risk of maternal mortality and adverse pregnancy outcomes (14, 114). These vasodilators include calcium channel blockers (CCB) (4, 6, 115), prostaglandins and associated analogs (7, 50, 51, 55, 116) and phosphodiesterase inhibitors (PDE-I) (117), but no endothelin receptor antagonists due to the teratogenic potential (118, 119). Pieper et al. suggested that pharmacological treatment of PAH should be started at ≥3 months before delivery, because the optimal effects did not appear until 3 months later (14). However, since the use of pulmonary vasodilators in pregnant women may endanger the safety of the fetus, their application must be evaluated with their standard formulations and usage requiring additional support by high-quality evidence-based research.

Prostaglandins and analogs

Prostacyclin can inhibit smooth muscle proliferation, reverse vascular remodeling, expand pulmonary and systemic circulation, enhance right ventricular function and exert anti-platelet effects (120). However, thrombocytopenia and bleeding-related complications may occur after the patients are treated with anticoagulants and prostacyclin at the same time. Therefore, blood routine and coagulation function parameters should be monitored closely (45). Indications of initiation use of prostaglandins are typically patients with WHO FC class III-IV PAH or impaired right ventricular function (88, 121–123).

At present, epoprostenol is the most widely used targeted drug in pregnant women with PAH (62%), which is also the first-line drug for the treatment of pregnancy with PAH or Eisenmenger syndrome (52, 124–126). Epoprostenol can improve exercise capacity, quality of life and survival rate (120). Due to its slow onset time and short half-life, it is recommended to commence treatment with this drug ≥8 weeks prior to delivery through the central venous catheter (120). It can also be used postpartum for preventing pulmonary hypertension crisis and right heart failure (127, 128). There is a lack of data and experience on the safety of this drug on the fetus, but several studies showed that it did not cause fetal malformation or intrauterine growth restriction in the third trimester (55, 116). Adverse reactions associated with the long-term use of epoprostenol may include facial flushing, headache, diarrhea, abdominal pain, uterine contractions, and postpartum hemorrhage. However, dosage reduction is only required when the adverse reactions become severe.

Iloprost is an inhaled prostacyclin analog that is frequently used to relieve dyspnea during surgery. The onset time is generally 15–20 min and the duration of drug effects is 1–2 h (125, 127, 129). Compared with intravenous administration, short-term application of aerosol iloprost inhalation tend to be more effective in reducing pulmonary arterial pressure (6, 7, 55). At present, there is no evidence indicating that inhaled iloprost can cause maternal mortality or congenital fetal anomalies. However, it was indicated that inhalation of iloprost within 24 weeks of gestation and perinatal period can significantly reduce the risk of fetal malformations and mortality (55, 114, 130). It is noteworthy that intravenous epoprostenol should be applied if the disease worsens after inhaling iloprost (52, 114). Inhaled prostaglandins are generally used for patients with less severe symptoms of PAH due to the short half-time caused by intermittent nebulized administration, which may lead to rebounds in pulmonary artery pressure (13, 55). However, it is a sign of serious condition if patients with PAH take iloprost before conception.

Treprostinil can be administered through various means, including subcutaneous infusion, intravenous and oral administration (131). This drug can be used for patients with WHO cardiac function class II-IV or NYHA III-IV PAH. It has been reported to significantly improve the 6-min walking distance, peripheral blood oxygen saturation and cardiac function (132). However, some patients (about 8%) refused to use this drug due to the infusion-site pain (133).

CCBs

A number of pregnant women with PAH may benefit from CCBs. However, CCBs are only typically used in patients whose acute pulmonary vasodilation test results are positive (4, 6, 85, 115). Diltiazem is the first choice CCBs for patients with fast heart rhythm, whereas nifedipine is used for patients with
slow heart rhythm. The minimum dose should be used at first with the dose increasing gradually according to blood pressure, cardiac rhythm, heart rate, electrocardiogram results and clinical symptoms until the maximum tolerated dose is reached. If the right heart structure and function remain at physiological levels and the pulmonary arterial pressure is normal or close to normal (mean pulmonary arterial pressure ≤30 mmHg and pulmonary vascular resistance <4 WU) after receiving CCB therapy, it can be judged that the patient is continuously sensitive to CCBs, meaning that it can be applied chronically. If there is no satisfactory response, additional PAH therapy should be instituted. However, various studies showed that CCBs are not able to mediate long-term vasodilation effects on patients with PAH, where exposure to CCBs in the third trimester may increase the risk of neonatal seizures (Odd ratio = 3.6) (134, 135). Therefore, it is necessary to consider the gradual conversion from CCBs to prostaglandins or analogs or PDE-I if cardiac function and pulmonary artery pressure are not maintained at normal levels (127).

PDE-I

PDE-5 inhibitors are the priority drug for women with WHO cardiac function class I-II PAH or normal right ventricular function (5, 71, 136). The expression levels of PDE-5 in the right ventricular myocardiun are frequently found to be increased in patients with PAH. PDE-5 inhibitors can reverse this change to relax vascular smooth muscles and reduce the pulmonary artery pressure (6). In addition, the use of PDE-5 inhibitors does not change lactate levels or pH levels in the fetus. Sildenafil is the most extensively applied PDE-5 inhibitor. It has been previously found that sildenafil can significantly improve the clinical symptoms, cardiac function, hemodynamic indices and pregnancy outcomes (111). It can also increase the rate of successful vaginal delivery and reduce the incidence of premature births or infants with low birth weights (130, 136, 137). If cardiac function continues to deteriorate and the pulmonary vascular resistance increases after oral sildenafil treatment, inhaled iloprost may be considered to relieve symptoms (136, 137). In addition, a previous study indicated that five pregnant women with PAH who received PDE-5 inhibitors and prostacyclin intravenously did not show significant maternal and infant complications during long-term follow-up at the breastfeeding stage (84).

Although sildenafil is widely used, its safety during requires further study. In 2021, a study focusing on 77 infants born to women who were treated with PDE-5 inhibitors during pregnancy found that nine infants were premature, six had small statures for their gestational age, five scored <8 in their 5-min appearance, pulse, grimace, activity and respiration tests, 18 were admitted to the neonatal intensive care unit and eight were diagnosed with respiratory and cardiovascular diseases (138). Furthermore, there is no clinical evidence to support the efficacy of vardenafil and tadalafil in pregnant women with PAH at present.

Statins

In addition to hypolipidemic effects, statins also have reported anti-inflammatory, anti-proliferative and apoptotic effects. A large number of clinical and experimental studies revealed that statins can reduce the pulmonary artery pressure and improve pulmonary vascular remodeling by promoting apoptosis, inhibiting cell proliferation, anti-inflammatory effects, inhibiting Rho kinase signaling and endothelin-1 release (139–142). Although statins also did not increase the rate of birth defects or the rate of fetal teratogenicity, the sample size was relatively small (78). Although statins are generally not recommended during pregnancy and lactation at present, they may be used for the long-term treatment of postpartum PAH after lactation (66, 79).

ECMO

ECMO is an advanced respiratory and circulatory support technology that has been proposed for patients with acute reversible respiratory failure (143). ECMO can maintain the oxygenation status of patients with PAH when cardiac function is decompensated (144, 145). Various case reports suggested that ECMO treatment in the majority of pregnant women with PAH conferred favorable pregnancy outcomes (146–148). However, it has also been reported that patients with PAH receiving ECMO did not survive beyond 3 months after delivery due to severe right heart failure (149). In addition, the continuous operation of ECMO requires systemic anticoagulation, where the continuous oozing of the surgical incision may lead to severe coagulation dysfunction (150, 151). Due to the small sample size reported thus far, further studies on larger sample sizes are warranted.

Operative therapy

PAH secondary to a known cardiopulmonary disease requires the aggressive treatment of primary disease, with procedures including biventricular pacing and cardiac operation (85). Cardiac surgery under cardiopulmonary bypass may be considered for patients who have responded to drug therapy but have opportunities for surgery. Surgery should be performed between 13 and 28 weeks of gestation. If the gestational week is >26 weeks, then cesarean section can be considered to terminate the pregnancy before performing the cardiopulmonary bypass operation. If the gestational week is >28 weeks, cardiac surgery can be considered after vaginal delivery. However, the risk of maternal and fetal mortality remains high during cardiopulmonary bypass operation. Cardiac surgery is
recommended only when drug or other forms of interventional therapy fails and the pregnant individual is in mortal danger (1, 88, 152).

For patients with chronic thromboembolic PAH, pulmonary endarterectomy is a possible curative method, although not all patients are suitable for this form of surgical treatment. Chronic thromboembolic PAH may also require postpartum thrombectomy or lung transplantation (1,46). High-risk patients who decide to continue pregnancy should be promptly evaluated for lung transplantation (6).

Conclusions

PAH is considered to be an irreversible disease. Strict contraception or early termination of pregnancy is recommended for PAH of any severity. However, effective early management is important for improving the prognosis for pregnant women with PAH first discovered during pregnancy or strongly required to continue pregnancy. Strategies, such as anticoagulation therapy, PAH-specific therapy and operative therapy, should be considered. Since pregnancy with PAH is a rare condition, the majority of relevant studies are retrospective studies based on case reports and case series analysis, which have low levels of evidence-based medical evidence. Therefore, additional prospective multi-center studies should be conducted in the future to optimize the clinical management strategies for pregnant women with PAH.

Author contributions

XZ and ZH conducted the study conceptualization, writing, and review of the manuscript. Both authors contributed to the review and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cikós R, Bonis MD, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Rev Esp Cardiol. (2019) 72:161. doi: 10.1016/j.rec.2018.12.003

2. Hooper MM, Humbert M, Souza R, Idrees M, Kawut SM, Slwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. (2016) 4:306–22. doi: 10.1016/s2213-2600(15)00543-3

3. Weiss BM, Zemp I, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. (1998) 31:1650–7. doi: 10.1016/s0735-1097(98)00162-4

4. Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J. (2009) 30:256–65. doi: 10.1093/eurheartj/ehs597

5. Duarte AG, Thomas S, Safdar Z, Torres F, Pacheco LD, Feldman J, et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest. (2013) 143:1330–6. doi: 10.1378/chest.12-0528

6. Jais X, Olsson KM, Barbera JA, Blanco I, Torbicki A, Peacock A, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J. (2012) 40:881–5. doi: 10.1183/09031936.0041211

7. Kiely DG, Condiffe R, Webster V, Mills GH, Wrench I, Gandhi SV, et al. Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. J Am Coll Cardiol. (2010) 55:117–45. doi: 10.1016/j.jacc.2009.11.041

8. Kamp JC, van Kaisenberg C, Greve S, Winter L, Park DH, Fuge J, et al. Pregnancy in pulmonary arterial hypertension: mid-term outcomes of mothers and offspring. J Heart Lung Transplant. (2021) 40:229–33. doi: 10.1016/j.healun.2020.12.002

9. Humbert M, Kovacs G, Hooper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/EUR guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. (2022) 43:117–731. doi: 10.1093/eurheartj/ehac237

10. D’Alto M, Di Maio M, Romeo E, Argiento P, Blasi E, Di Vilio A, et al. Echocardiographic probability of pulmonary hypertension: a validation study. Eur Respir J. (2022) 60:2125648. doi: 10.1183/13993003.2125648-2021

11. Simonneau G, Montani D, Celerier MAS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. (2019) 53:1801913. doi: 10.1183/13993003.01913-2018

12. Corbach N, Berlier C, Lichtblau M, Schwartz EL, Gauthais E, Groth A, et al. Favorable pregnancy outcomes in women with well-controlled pulmonary arterial hypertension. Front Med. (2021) 8:689. doi: 10.3389/fmed.2021.689764

13. Hennes AR, Kieley DG, Cockrill BA, Safdar Z, Wilson VJ, Al Hazmi M, et al. Statement on pregnancy in pulmonary hypertension from the pulmonary vascular research institute. Pulm Circ. (2015) 5:435–65. doi: 10.1086/682230

14. Pieper PG, Lameijer H, Hoendermis ES. Pregnancy and pulmonary hypertension. Best Pract Res Clin Obstet Gynaecol. (2014) 28:579–91. doi: 10.1016/j.bpo.2014.03.003

15. Olsson KM, Jais X. Birth control and pregnancy management in pulmonary hypertension. Semin Respir Crit Care Med. (2013) 34:681–8. doi: 10.1055/s-0033-1354338

16. Galib N, Humbert M, Vachery JL, Gibbs S, Lang J, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol. (2016) 69:177. doi: 10.1016/s0300-8936(16)00054-0

17. Famuyide AO, Hopkins MR, El-Nashar SA, Creedon DJ, Vasdev GM, Driscoll DJ, et al. Hysteroscopic sterilization in women with severe cardiac disease: experience at a tertiary center. Mayo Clin Proc. (2008) 83:431–8. doi: 10.4065/83.4.431

18. Običan SG, Cleary KL. Pulmonary arterial hypertension in pregnancy. Semin Perinatol. (2014) 38:289–94. doi: 10.1055/s-0033-1355438

19. van der Linde D, Konings EJ, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, et al. Birth prevalence of congenital heart disease worldwide.
a systematic review and meta-analysis. J Am Coll Cardiol. (2011) 58:2241–7. doi: 10.1016/j.jacc.2011.08.025

20. Gill HK, Splitt M, Sharland GK, Simpson JM. Patterns of recurrence of congenital heart disease: an analysis of 6,640 consecutive pregnancies evaluated by detailed fetal echocardiography. J Am Coll Cardiol. (2003) 42:923–9. doi: 10.1016/S0735-1097(03)00583-2

21. Yucek EL, DeSaria Yeh D. Pregnancy in women with congenital heart disease. Curr Treat Options Cardiovasc Med. (2017) 19:73. doi: 10.1007/s11936-017-0572-0

22. Morrell NW, Aldred MA, Chung WW, Elliott CG, Nichols WC, Soubrier F et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. (2019) 53:1801899. doi: 10.1183/13993003.001899-2018

23. Martinez MV, Rutherford JD. Pulmonary hypertension in pregnancy. Cardiol Rev. (2013) 21:167–73. doi: 10.1097/CRD.0b013e318275c7bc

24. Saalder Z. Pulmonary arterial hypertension in pregnant women. Ther Adv Respir Dis. (2013) 7:51–63. doi: 10.1177/1753489312461680

25. Korer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol. (2002) 187:1623–30. doi: 10.1067/mob.2002.127576

26. Werler MM, Sheehan JE, Mitchell AJA. Maternal medication use and risks of gastrointestinal and small intestinal atresia. Am J Epidemiol. (2002) 155:26–31. doi: 10.1093/aje/155.1.26

27. Perkin RM, Levin DL, Clark R. Serum salicylate levels and right-to-left ductus shunts in newborn infants with persistent pulmonary hypertension. J Pediatr. (1980) 96:721–6. doi: 10.1016/s0022-3476(80)80753-0

28. Alano MA, Ngoungou E, Ostrea Jr EM, Konduri GG. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics. (2001) 107:519–25. doi: 10.1542/peds.107.3.519

29. James AH, Brancaniz LR, Price T. Aspirin and reproductive outcomes. Obstet Gynecol Surv. (2008) 63:49–57. doi: 10.1097/OGS.0b013e31815e7831

30. Collins E. Maternal and fetal effects of acetaminophen and salicylates in pregnancy. Obstet Gynecol (1981) 58:657–62

31. CLASP collaborative group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. Br J Obstet Gynaecol. (1995) 102:861–8. doi: 10.1111/j.1471-0528.1995.tb01872.x

32. Kristensen DM, Hass U, Le tenure L, Lottrup G, Jacobson PR, Desdoits-Lethimonier C et al. Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. Hum Reprod. (2011) 26:235–44. doi: 10.1093/humrep/deq323

33. Yurdakök M. Fetal and neonatal effects of anticoagulants used in pregnancy: a review. Turk J Pediatr. (2012) 54:207–13.

34. Winger EE, Reed JL, A. retrospective analysis of fondaparinux versus enoxaparin. J Vasc Interv Radiol. (2007) 18:1623–30. doi: 10.1016/j.jvir.2006.10.013

35. Calzolari E, Barisic I, Loane M, Morris J, Wellesley D, Dolk H et al. Absence of transplacental passage of the low molecular weight heparin, fondaparinux, and development of school-age children. Thorax. (2001) 56:609–13.

36. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic venous thromboembolism in pulmonary arterial hypertension. Eur Heart J. (2004) 25:1012–20. doi: 10.1093/eurheartj/ehi283

37. De Carolis S, di Pasquo E, Rossi E, Del Sordo G, Buonomo A, Schiavino M. In utero exposure to coumarins and cognition at 8 to 14 years old. Pediatrics. (2011) 128:41. doi: 10.1542/peds.2010-1005

38. Wesseling J, Van Driel D, Heymans HS, Rosendaal FR, Geven-Boere LM, Sminkovskiy M et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thorax. (2001) 56:609–13.

39. van Driel D, Wesseling J, Sauer PJ, Touwen BC, van Der Veer E, Heymans HS. Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow up findings, and pathogenesis. Teratology. (2002) 66:127–40. doi: 10.1002/tera.10054

40. Stewart R, Tzaou D, Olson G, Duarte AG. Pregnancy and primary pulmonary hypertension: successful outcome with epoprostenol therapy. Chest. (2001) 119:973–5. doi: 10.1378/chest.119.3.973

41. Timofeev J, Ruiz G, Fries M, Driggers RW. Intrauterine epoprostenol for management of pulmonary arterial hypertension during pregnancy. AJP Rep. (2013) 3:71–4. doi: 10.1530/aprep.113.0331819

42. Galié N, Corris PA, Frost A, Girgei RE, Granton J, Jing ZC et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. (2013) 62:D60–72. doi: 10.1016/j.jacc.2013.10.031

43. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. (2008) 31:891–901. doi: 10.1183/09031936.00097107

44. Elliot CA, Stewart P, Webster VJ, Mills GH, Hutchinson SP; Howarth ES, et al. The use of iloprost in early pregnancy in patients with pulmonary arterial hypertension. Eur Respir J. (2007) 29:668–73. doi: 10.1183/09031936.05.182504

45. Opitz CF, Wensel R, Winkler J, Halanck M, Bruch L, Kleber FX, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. (2005) 26:1895–902. doi: 10.1093/eurheartj/ehi283

46. Hooper MM, Gall H, Feyrhar HJ, Halanck M, Ghofrani HA, Winkler J et al. Long-term outcome with inhaled iloprost in pulmonary arterial hypertension. Eur Respir J. (2009) 34:152–7. doi: 10.1183/09031936.00134008

47. Rosengarten D, Kramer R. Pregnancy in a woman with pulmonary hypertension: favorable outcome with intravenous treprostinil. Clin Exp Obstet Gynecol. (2015) 42:390–1.

48. Nadler ST, Edelman JD. Inhaled treprostinil and pulmonary arterial hypertension. Curr Health Risk Manag. (2010) 6:1115–24. doi: 10.2147/ehrm.s14777

49. Feldman J, Halob N, Fann J, Radosевич J. Treprostinil in the treatment of pulmonary arterial hypertension. Future Cardio. (2020) 16:547–72. doi: 10.2121/fc.2020-0021

50. Skoro-Sajer N, Lang I, Naeije R. Treprostinil for pulmonary hypertension. Curr Vas Health Risk Manag. (2008) 4:507–13. doi: 10.2147/ehrm.s2477

51. Lindegaard Pedersen M, Krüger M, Grimm D, Inghfer M, Weiklab M. The prostacyclin analogue treprostinil in the treatment of pulmonary hypertension. Basic Clin Pharmacol Toxicol. (2019) 126:32–42. doi: 10.1111/bcpt.13305

52. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VE et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the treprostinil sodium inhalation used in the management
of pulmonary arterial hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant. (2011) 30:1327–33. doi: 10.1016/j.healun.2011.08.019

64. Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. (2013) 127:624–33. doi: 10.1161/circulationaha.112.124388

65. Tapson VE, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. (2012) 142:1383–90. doi: 10.1378/chest.11-2212

66. Pieper PG. Use of medication for cardiovascular disease during pregnancy. Nat Rev Cardiol. (2013) 12:718–29. doi: 10.1038/nrcardio.2013.172

67. Sandovalo J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. (2011) 184:1383–90. doi: 10.1164/rccm.201105-0901OC

68. Packer M. Therapeutic application of calcium-channel antagonists for pulmonary hypertension. Am J Cardiol. (1985) 55:196b–201b. doi: 10.1016/0002-9149(85)90631-9

69. Krinkler DM, Rowland E. Clinical value of calcium antagonists in treatment of cardiovascular disorders. J Am Coll Cardiol. (1983) 1:355–64. doi: 10.1016/s0735-1097(83)80035-7

70. Davis RL, Eastman D, McPhillis H, Raela MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoeconomics Drug Saf. (2011) 20:138–45. doi: 10.1002/pds.2068

71. Tacyo G, Ekim NN, Cengel A. Dramatic response of a patient with pregnancy induced idiopathic pulmonary arterial hypertension to sildenafil treatment. J Obstet Gynaecol Res. (2010) 36:414–7. doi: 10.1111/j.1447-0756.2009.01366.x

72. Goland S, Tsai F, Habib M, Zannouh Mohamed M, Goodwin TM, Elkayam U. Favorable outcome of pregnancy with an elective use of propranolol and sildenafil in women with severe pulmonary hypertension. Cardiology. (2010) 115:205–8. doi: 10.1159/000287638

73. Ala M, Mohammad Jafari R, Dehour P. Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: thinking about new indications. Fundam Clin Pharmacol. (2015) 29:355–59. doi: 10.1111/fcp.12028

74. Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract. (2006) 60:967–75. doi: 10.1111/j.1742-1241.2006.01049.x

75. Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc. (2003) 78:1207–13. doi: 10.4065/78.12.1207

76. Dhallon R. The management of neonatal pulmonary hypertension. Arch Dis Child Fetal Neonatal Ed. (2012) 97:F223–8. doi: 10.1136/adc.2011.200991

77. Cross DM, Horder E, Derzi M, Owen K, Stavros FL. An evaluation of atrioventricular block: perinatal risks and review of management. J Electrocardiol. (2012) 45:463–70. doi: 10.1016/j.jelectrocard.2011.06.005

78. Winterfeld U, Allignol A, Panchaud A, Rothuizen LE, Merlob P, et al. Incidence and clinical relevance of supraventricular tachyrhythmias in pulmonary hypertension. Am J Heart. (2007) 153:127–32. doi: 10.1016/j.amjheart.2006.09.008

79. Kirchhoff F, Benussi S, Kotecha D, Ahlsson A, Attar D, Casadesus B, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with the EACTS. Europace. (2010) 18:1609–78. doi: 10.1093/europace/euq001

80. Kockova R, Kocka V, Kierman T, Faby GJ. In utero-induced coarctation of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol. (2007) 18:545–51. doi: 10.1111/j.1540-8167.2006.00752.x

81. Katriinis DG, Boriani G, Cosio FG, Hindricks G, Jais P, Josephson ME, et al. European heart rhythm association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by heart rhythm society (HRS), Asia-pacific heart rhythm society (APHRS), and sociedad latinoamericana de estimulación cardíaca y electrosotología (SALCACE). Europace. (2017) 19:465–513. doi: 10.1093/europace/eux170

82. Driver K, Chisholm CA, Darby AE, Malmotha R, Dimarco JP, Ferguson JD. Catheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol. (2015) 26:698–702. doi: 10.1111/jce.12675

83. Chen G, Sun G, Xu R, Chen X, Yang L, Bai Y, et al. Zero-fluoroscopy catheter ablation of severe drug-resistant arrhythmia guided by Ensite NavX system during pregnancy: two case reports and literature review. Medicine. (2016) 95:e487. doi: 10.1097/md.00000000000004487

84. Hidaka N, Chiba Y, Fukushima K, Wake N. Pregnant women with complete atrioventricular block: perinatal risks and review of management. Pacing Clin Electrophysiol. (2011) 34:1161–76. doi: 10.1111/j.1540-8159.2011.03177.x

85. Suri V, Keepanasseril A, Aggarwal N, Vaijyargya R, Chopra S, Rohilla M. Maternal complete heart block in pregnancy: analysis of four cases and review of management. J Obstet Gynaecol Res. (2009) 35:434–7. doi: 10.1111/j.1447-0756.2008.00961.x

86. Natale A, Davidson T, Geiger MJ, Newbly K. Implantable cardioverter-defibrillators and pregnancy: a safe combination? Circulation. (1997) 96:2808–12. doi: 10.1161/01.ctr.96.28.2808

87. Ladouceur M, Benoit L, Radojevic J, Dauphin C, Ladouceur M, Benoit L, Radojevic J, Dauphin C. High-risk cardiac disease in pregnancy: Part I. J Am Coll Cardiol. (2016) 68:396–410. doi: 10.1016/j.jacc.2015.05.048
104. Elkahy H, Golan D, Pieper PG, Sylversides CK. High-risk cardiac disease in pregnancy: Part II. J Am Coll Cardiol. (2016) 68:502–16. doi: 10.1016/j.jacc.2016.05.016 – 9A. doi: 10.1016/j.jacc.2016.05.016

105. van Hagen IM, Roos-Hesselink JW, Ruys TP, Merz WM, Golan D, Gabriel H, et al. Pregnancy with women in a mechanical heart valve: data of the European society of cardiology registry of pregnancy and cardiac disease (ROPAC). Circulation. (2015) 132:132–42. doi: 10.1161/circulationaha.115.015242

106. McLintock C. Thromboembolism in pregnancy: challenges and controversies in the prevention of pregnancy-associated venous thromboembolism and management of anticoagulation in women with mechanical prosthetic heart valves. Best Pract Res Clin Obstet Gynaecol. (2014) 28:519–36. doi: 10.1016/j.bpbogyn.2014.03.001

107. Kho O, Tuy KH, Shintaku I, Lip GY. Novel oral anticoagulants. Int J Clin Pract. (2009) 63:630–41. doi: 10.1111/j.1742-1241.2009.02011.x

108. Hoeltezen M, Beck E, Meixner K, Schafer C, Kretz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German embroytox pharmacovigilance centre. Clin Res Cardiol. (2016) 105:117–26. doi: 10.1007/s00392-015-0893-5

109. Areia AL, Mota-Pinto A. Experience with direct oral anticoagulants in pregnancy - a systematic review. J Perinat Med. (2012) 40:457–61. doi: 10.1515/jpm-2012-0047

110. Lameije H, Aalberts JJ, van Veldhuisen DJ, Meijer K, Pieper PG. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. Thromb Res. (2018) 169:123–7. doi: 10.1016/j.thromres.2018.07.022

111. Bassili-Marcus AM, Yuan C, Oropello J, Manasia A, Kohli-Seth R, Benjamin E. Pulmonary hypertension in pregnancy: critical care management. Pulm Med. (2012) 2012:799407. doi: 10.1155/2012/799407

112. Bian C, Wei Q, Liu X. Influence of heart-valve replacement of warfarin anticoagulant therapy on perinatal outcomes. Arch Gynecol Obstet. (2012) 285:347–51. doi: 10.1007/s00404-011-1962-2

113. Bates SM, Greer IA, Middeldorp S, Veerstra DL, Prabulos AM, Vandvik PO, et al. Thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed. American college of chest physicians evidence-based clinical practice guidelines. Chest. (2012) 141:e965S–736S. doi: 10.1378/chest.11-2300

114. Daimon A, Kamiya CA, Iwanaga N, Yoshimitsu J. Management of pulmonary vasodilator therapy in three pregnancies with pulmonary arterial hypertension. J Obstet Gynaecol Res. (2017) 43:935–8. doi: 10.1111/jog.13279

115. Bonnin M, Mercier F, Silbon O, Roger-Christoph S, Jaïs X, Humbert M, et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. (2003) 109:1133–7, discussion 5A–6A. doi: 10.1097/00000542-200306000-00012

116. Avaladzic M, Sandrock C, Hosko A, Allen R, Albertson TE. Epoprostenol in pregnant patients with secondary pulmonary hypertension: two case reports and a review of the literature. Treat Respir Med. (2004) 3:29–34. doi: 10.2165/00151829-200404030-00004

117. Lackassee HI, Germain AM, Valdés G, Fernández MS, Allamand A. A comprehensive review of treprostinil pharmacokinetics via four routes of administration. Clin Pharmacokinet. (2014) 53:1485–505. doi: 10.1007/s40262-016-0409-0

118. Wang RC, Jiang FM, Zhai R, Peng XY, He CY, et al. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Respir Med. (2014) 108:531–7. doi: 10.1016/j.rmed.2014.01.003

119. Galbi N, Ghofrani HA, Toribbci A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate derangement in pulmonary arterial hypertension. N Engl J Med. (2003) 353:2148–57. doi: 10.1056/NEJMoa005010

120. Wang RC, Jiang FM, Zheng QI, Li CT, Peng XY, He CY, et al. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Respir Med. (2014) 108:531–7. doi: 10.1016/j.rmed.2014.01.003

121. Wu D, Cuesta CE, Segovia Chacón S, Engeland A, Broe A, Damkier P, Furu K, et al. PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol. (2014) 172:581–7. doi: 10.1016/j.ijcard.2014.01.102

122. Costa CE, Segovia Chacón S, Engeland A, Broe A, Damkier P, Furkó P, et al. Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia. Acta Obstet Gynecol Scand. (2021) 100:2111– 9. doi: 10.1111/aogs.14251

123. Chen D, Zhou D, Qian J, Chen F, Guan L, Dong L, et al. Atorvastatin prevents dehydromonocrotaline-induced pulmonary hypertension in beagles. Exp Lung Res. (2012) 38:333–43. doi: 10.3109/01902148.2012.702852

124. Wilkins MR, Ali O, Bradlow W, Wharton J, Tegtmeier A, Rhodes CE, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med. (2010) 181:1106–13. doi: 10.1164/rccm.200911-1696oc

125. Ali OF, Gwoscott EL, Butrous GS, Wharton J. Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells. Respir Cell. (2011) 12:137. doi: 10.1089/res.2011.9921-1213

126. Cunningham JA, Devine PC, Jelic S. Extrapulmonary membrane oxygenation in pregnancy. Obstet Gynecol. (2008) 106:792– 5. doi: 10.1097/00006250-200805000-00026

127. Zhang J, Lu J, Zhou H, Xu X, Ye Q, Ou Q, et al. Perioperative management of pregnant women with idiopathic pulmonary arterial hypertension: an observational case series study from China. J Cardiothorac Vasc Aneth. (2018) 32:2547–59. doi: 10.1053/j.jvca.2018.01.043

128. Zhang ZN, Jiang X, Zhang R, Li XL, Wu RX, Zhao QH, et al. Sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart. (2011) 97:1876–81. doi: 10.1136/heartjnl-2011-300344

129. Martin SR, Edwards A. Pulmonary hypertension and pregnancy. Obstet Gynecol. (2019) 134:974–87. doi: 10.1097/AOG.0000000000003549

130. Goya M, Meseguer ML, Mercid C, Suy A, Monsfort V, Domingo A, et al. Successful pregnancy in a patient with pulmonary hypertension associated with mixed collagen vascular disease. J Obstet Gynaecol Res. (2014) 40:191. doi: 10.1016/j.jogre.2012.070663
144. Meng ML, Landau R, Viktorsdottir O, Banayan J, Grant T, Bateman B, et al. Pulmonary hypertension in pregnancy: a report of 49 cases at four tertiary north American sites. *Obstet Gynecol.* (2017) 129:511–20. doi: 10.1097/aog.0000000000001896

145. Abid Memon H, Safdar Z, Goodarzi A. Use of extracorporeal membrane oxygenation in postpartum management of a patient with pulmonary arterial hypertension. *Case Rep Pulmonol.* (2018) 2018:7031731. doi: 10.1155/2018/7031733

146. Ye J, Chen JY, Xu N, Wu B, Wang ZP, Xu HY, et al. Bilateral lung transplantation after caesarean section in pregnancy with severe pulmonary arterial hypertension: a case report. *Medicine.* (2019) 98:e18109. doi: 10.1097/md.0000000000018109

147. Hara R, Hara S, Ong CS, Schwartz G, Sciortino C, Hibino N. Cesarean section in the setting of severe pulmonary hypertension requiring extracorporeal life support. *Gen Thorac Cardiovasc Surg.* (2017) 65:322–4. doi: 10.1007/s11748-016-0729-x

148. Weinberg L, Kay C, Liskaer F, Jones D, Tay S, Jaffe S, et al. Successful treatment of peripartum massive pulmonary embolism with extracorporeal membrane oxygenation and catheter-directed pulmonary thrombolytic therapy. *Anesth Intensive Care.* (2011) 39:486–91. doi: 10.1177/0310057x110390323

149. Roldan T, Villamañán E, Rios JJ, Waxman AB. Assessment of the quality of anticoagulation management in patients with pulmonary arterial hypertension. *Thromb Res.* (2017) 160:83–90. doi: 10.1016/j.thromres.2017.10.024

150. Reyfmann L, Morau E, Dechaud H, Fraiper JM, Hedon B. Extracorporeal membrane oxygenation therapy for circulatory arrest due to postpartum hemorrhage. *Obstet Gynecol.* (2006) 107:511–4. doi: 10.1097/01.Aog.0000173970.67736.92

151. Robertson LC, Allen SH, Konamme SP, Chestnut J, Wilson P. The successful use of extra-corporeal membrane oxygenation in the management of a pregnant woman with severe H1N1 2009 influenza complicated by pneumonitis and adult respiratory distress syndrome. *Int J Obstet Anesth.* (2010) 19:443–7. doi: 10.1016/j.ijoa.2010.04.010

152. Reichenberger F, Pepke-Zaba J, McNeil K, Parameshwar J, Shapiro LM. Atrial septostomy in the treatment of severe pulmonary arterial hypertension. *Thorax.* (2003) 58:797–800. doi: 10.1136/thorax.58.9.797